The endocannabinoid system has long been recognized as a promising target for PTSD treatment.
Here, a 2018 literature review summarizes the risks and benefits of cannabis as a treatment option. Watch our video adaptation, and review the source literature, below:
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2XgnrXn inside the CED Foundation Archive
To explore related information, click the keywords below:
Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain
Some of the non-psychoactive cannabinoids in cannabis, cannabidiol (CBD) and cannabinol (CBN), have recently been found to produce analgesic effects (pain relief) in mouse models. A combination of CBD and CBN causes a decrease in sensitization of muscles, leading researchers to believe the combination could provide relief for those suffering from chronic muscle pain disorders. Cannabis products are already being prescribed for chronic pain disorders and this new study provides evidence that cannabis-based medicine can also be applicable when treating chronic pain associated with disorders such as fibromyalgia and temporomandibular disorders.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2L1AF8d inside the CED Foundation Archive
A literature review from 2009 (10 years ago) summarizes the anti-cancer properties of cannabis, concluding that various cannabinoids might inhibit cancer cell growth and tumor growth. In particular, cannabis shows promise to help treat colon, skin, prostate, and breast cancer.
This paper is also stored here: http://bit.ly/2J1XS8A inside the CED Foundation Archive
To explore related information, click the keywords below:
In overarching trends, one pattern that is seen in the medical literature is a greater tendency for males to be more likely to develop drug abuse disorders than female counterparts, whilst females are more likely to develop anxiety disorders than male counterparts.
Of course, these trends are merely observational patterns in the current literature, which represents a biased perspective of biased subjects, and certainly not etched in stone. Further, many people do not conform to one pre-determined organization system as simple as gender to help educate whether they would be likely to develop drug dependence or anxiety, and even others don’t conform to a single gender. So, a sizeable grain of salt must be taken with what we understand from this literature.
That given, the relevant punch line here is what role might cannabis play in inducing or reducing anxiety across sexes, and how does cannabis might relate to addiction/dependence.
We are still at early stages of these important questions, but one recent study found, that female rats were significantly more likely than male rats to experience anxiety when given large doses of cannabis.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2J15XdL inside the CED Foundation Archive
To explore related information, click the keywords below:
Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients
Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2KXTb0Y inside the CED Foundation Archive
To explore related information, click the keywords below:
Bipolar disorder and the endocannabinoid system
A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2FfJXK6 inside the CED Foundation Archive
To explore related information, click the keywords below:
Title of study: Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study
After legalization in 2018, many Canadian provinces implemented “zero tolerance” policies for drivers who have THC in their systems. But a new study from the University of British Columbia suggests that Canada’s drug-impaired driving laws may be unnecessarily strict. According to researchers, there is no link between THC levels below 5ng/mL and increased risk of car accidents.
Note: Considering the potentially grave risk to life and health for modern culture to make the wrong interpretation of the potential dangers of the effects of cannabis consumption on driving, it is critical for the industry to approach the circumstances with delicacy and diligence. Ideally, everyone involved will be motivated to learn as much as possible about the impact of cannabis on the risks of operating machinery and all will follow a cautious approach which will minimize the risk to all. To that end, it is important to consider and reconcile evidence from multiple perspectives.
The article:
“New study suggests low levels of THC in blood do not increase risk of car crash” https://www.straight.com/cannabis/1256476/new-study-suggests-low-levels-thc-blood-do-not-increase-risk-car-crash#
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2IVhSJY inside the CED Foundation Archive
To explore related information, click the keywords below:
Genome-wide association study implicates CHRNA2 in Cannabis Use Disorder
Roughly 9% of cannabis users become dependent. In a recent study, scientists identified a significant association between CHRNA2 gene expression and a diagnosis of Cannabis Use Disorder. In other words, genetics might help to explain why some people may find themselves more dependent upon cannabis than others.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2IVZJvJ inside the CED Foundation Archive
To explore related information, click the keywords below:
| A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments. |
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2IWFA8R inside the CED Foundation Archive
To explore related information, click the keywords below:
A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS
The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2FfLorA inside the CED Foundation Archive
To explore related information, click the keywords below: